FDA approves trade name Auryxia for Keryx’s ferric citrate
Keryx is a biopharmaceutical firm focused on bringing new therapies to market for patients with renal disease. In September 2014, Auryxia was approved by the FDA to control
Keryx is a biopharmaceutical firm focused on bringing new therapies to market for patients with renal disease. In September 2014, Auryxia was approved by the FDA to control
Under the deal, Allergan investors would receive $129.22 in cash and 0.3683 Actavis shares for each share of the Botox-maker’s common stock. The combination will create one of
Both the firms will explore the therapeutic potential of this new anti-PD-L1 antibody as a single agent as well as in various combinations with their broad portfolio of
As part of this deal, all of Roche’s rights to INO-5150, including the right to license the product to other parties, will be returned to Inovio, which now
The project will focus on non-valvular atrial fibrillation (NVAF) and will examine disease prevalence, treatment complications, such as hospital readmissions, as well as the use of evidence-based guidelines.
The randomized double blind trial included a total of 418 patients with treatment naïve BRAF wild-type unresectable Stage III and IV melanoma and they were given either Opdivo
A total of 239 subjects infected with HPV 16 and/or 18 were enrolled at 39 clinical sites across seven European countries including Belgium, Finland, France, Germany, the Netherlands,
The FDA approval is based on results from the Phase III AURELIA trial that showed Avastin plus chemotherapy reduced the risk of disease worsening or death (progression-free survival)
Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. The trial evaluated pembrolizumab at doses of 2mg/kg every three
The company said that due to its safety profile, the use of Lemtrada should be reserved for patients who have had an inadequate response to two or more